Jasper Therapeutics to Expand Mast Cell Portfolio, Initiates Asthma Study in Q4
Jasper Therapeutics (JSPR) said Monday it is expanding the company's mast cell development portfolio and will evaluate briquilimab, a conditioning agent for patients undergoing stem cell transplant, i
Analysts Offer Insights on Healthcare Companies: Adicet Bio (ACET), Jasper Therapeutics (JSPR) and Lucid Diagnostics (LUCD)
Jasper Therapeutics Announces Briquilimab Development Program in Asthma
PDF Version Expanding Portfolio of Mast Cell Programs with Plans to Initiate a Phase 1b/2a study in Patients with Asthma in Q4 2024Company to Host Key Opinion Leader Webinar on the Potential of B
Jasper Therapeutics to Present at Upcoming Investor Conferences in May
PDF Version REDWOOD CITY, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel anti
Spirit Airlines Posts Weak Results, Joins Integra LifeSciences, Bowlero And Other Big Stocks Moving Lower On Monday
U.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on Monday.Shares of Spirit Airlines, Inc. (NYSE:SAVE) fell sharply during Monday's session as the company reported a first-qu
Jasper Therapeutics Initiated at Buy by HC Wainwright & Co.
Jasper Therapeutics Initiated at Buy by HC Wainwright & Co.
Jasper Therapeutics (JSPR.US) was first covered by HC Wainwright & Co. with a buy rating, with a target price of $65.00.
Jasper Therapeutics (JSPR.US) was first covered by HC Wainwright & Co. with a buy rating, with a target price of $65.00.
HC Wainwright & Co. Initiates Coverage On Jasper Therapeutics With Buy Rating, Announces Price Target of $65
HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Jasper Therapeutics with a Buy rating and announces Price Target of $65.
Buy Rating Affirmed: Jasper Therapeutics' Briquilimab Shows Promising Outlook in Chronic Urticaria Treatment Market
Jasper Therapeutics, Inc.'s (NASDAQ:JSPR) Market Cap Dropped US$88m Last Week; Individual Investors Who Hold 36% Were Hit as Were Institutions
Key Insights The considerable ownership by individual investors in Jasper Therapeutics indicates that they collectively have a greater say in management and business strategy A total of 12 investors
Jasper Therapeutics Initiated at Outperform by Evercore ISI Group
Jasper Therapeutics Initiated at Outperform by Evercore ISI Group
Evercore ISI Group Initiates Coverage On Jasper Therapeutics With Outperform Rating, Announces Price Target of $65
Evercore ISI Group analyst Gavin Clark-Gartner initiates coverage on Jasper Therapeutics with a Outperform rating and announces Price Target of $65.
Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
PDF Version REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel an
RBC Starts Jasper Therapeutics at Outperform, Cites Market Opportunity
Jasper Therapeutics Initiated at Outperform by RBC Capital
Jasper Therapeutics Initiated at Outperform by RBC Capital
RBC Capital Initiates Coverage On Jasper Therapeutics With Outperform Rating, Announces Price Target of $70
RBC Capital analyst Gregory Renza initiates coverage on Jasper Therapeutics with a Outperform rating and announces Price Target of $70.
Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
PDF Version REDWOOD CITY, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel an
Buy Rating Affirmed for Jasper Therapeutics as Briquilimab Shows Market Potential in Chronic Urticaria Treatment
Analysts' Top Healthcare Picks: Jasper Therapeutics (JSPR), Alphatec Holdings (ATEC)
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria
PDF Version REDWOOD CITY, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel an
No Data